Airfreight Must Prepare for a New Wave of Pharma – ‘Current Processes Won’t Work’

Why It Matters

The next generation of pharma products will dominate future cargo volumes, forcing the air freight sector to overhaul handling, visibility, and regulatory processes to stay competitive and safe.

Key Takeaways

• DSV launches Air ThermoDirect corridor Luxembourg‑Indianapolis for pharma
• New cell, gene, and radioligand therapies demand faster, traceable transport
• Air cargo must shift from capacity focus to end‑to‑end control
• Airport ground handling may need commodity‑specific processes for radioactive shipments

Pulse Analysis

The air freight industry is at a crossroads as personalized medicines transition from clinical trials to commercial scale. Unlike traditional vaccines or bulk drugs, cell and gene therapies often have shelf lives measured in hours and must remain within narrow temperature windows. DSV’s Air ThermoDirect corridor exemplifies a proactive response, offering a streamlined route that reduces handling steps, cuts emissions, and provides real‑time temperature monitoring—key differentiators for pharmaceutical shippers seeking to protect product integrity.

Beyond the corridor, the broader logistics ecosystem faces structural challenges. Customs clearance must become synchronized across borders to eliminate delays that could render a therapy ineffective. Ground handlers at airports will need commodity‑specific protocols, especially for radioligands that pose radiation safety concerns. Airlines may have to redesign cargo holds to accommodate multiple small, high‑value shipments while maintaining segregation and temperature control, shifting the value proposition from sheer capacity to precision management.

Investors and operators who ignore these trends risk losing market share to specialized logistics firms that can guarantee 100% visibility and contingency planning. As personalized oncology treatments promise longer patient survival, the demand for reliable, ultra‑fast air transport will surge. Companies that embed end‑to‑end ownership—integrating cold‑chain technology, data analytics, and regulatory compliance—will set the new standard for pharma air cargo, driving both revenue growth and industry resilience.